Gabe Longoria joins 4basebio following a successful tenure as Chief Commercial Officer at Astrea Bioseparations Ltd. 4basebio ...

Under the agreement, UCB gains a non-exclusive license to leverage XtalFold for the discovery and engineering of biologics.

The newly approved methastatic Renal Cell Cancer (mRCC) Phase 1/2a trial began in 4Q24, and Genenta expects to treat six ...

GEMMA Biotherapeutics —a new therapeutics company founded by gene therapy pioneer Dr. Jim Wilson—has named May Orfali, MD, ...

Peptone, a biotech company developing novel therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases ...

Biopharmaceutical company Mabwell has announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821).

Boehringer Ingelheim has licensed Synaffix B.V.’s ADC technology, significantly bolstering its ADC portfolio with the goal of ...

Alchemab Therapeutics, a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies ...

Samsung Biologics, a global contract development and manufacturing organization (CDMO), has extended its collaboration with ...

Are you prepared for what’s next in DSCSA compliance?

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Galapagos plans to discontinue its small molecule discovery programs and seek potential partners to take over these assets, including the TYK2 inhibitor, GLPG3667, currently in Phase 2 for systemic ...